Camurus’ rights issue of 403 MSEK has been oversubscribed. The rights issue was carried out to secure financing of the launch and marketing of Buvidal in Europe and Australia.
Camurus’ rights issue of 403 MSEK has been oversubscribed. The rights issue was carried out to secure financing of the launch and marketing of Buvidal in Europe and Australia. Buvidal is Camurus’ first approved drug for the treatment of opioid dependence.
The rights issue was guaranteed by Sandberg Development.
Read more at Camurus’ website: https://www.camurus.com/pressreleases/
Latest news
2024-04-16
Research donation from Sandberg Development for increased knowledge about water
In April 2024, Sandberg Development donated 100 million Swedish kronor, distributed over a 10-year period, to Malmö…